A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


May 22, 2012

Rectal Microbicide Shows Better Safety in Laboratory Study

Laboratory testing of a modified version of the Viread (tenofovir) microbicide gel provides further evidence that it may be safe for rectal use, according to a paper published online ahead of print by the Journal of Antimicrobial Chemotherapy.

The encouraging results contribute to a better understanding of the gel’s tolerability, already evident in preliminary findings from a 65-person Phase I clinical trial reported at the 19th Conference on Retroviruses and Opportunistic Infections earlier this year in Seattle.

“The lining of the rectum is much more fragile than the vaginal epithelium, so we can’t be certain a product like tenofovir gel that is safe for vaginal use will be completely safe to use in the rectum,” said lead study author Charlene Dezzutti, PhD, of the University of Pittsburgh School of Medicine and the Microbicide Trials Network (MTN) in an accompanying news announcement. “We are very encouraged by our laboratory data that suggest the reformulated gel could be safer for rectal use, and serve as a dual compartment gel for use in both the vagina and rectum.”

The tenofovir gel that has been explored for vaginal use is hyperosmolar—it contains higher concentrations of sugars and salts, compared with those inside the cells of the rectum, which can cause the cells to expel too much water. Not only can this result in side effects, such as cramping and diarrhea, but it can actually increase the chances of HIV infection during anal intercourse.

To make the tenofovir gel more amenable to rectal use, researchers from CONRAD, a research organization that holds the rights to develop the gel, reformulated it with a reduced amount of glycerin, a common additive found in many gel-like products.

The laboratory evaluations conducted by Dezzutti and her colleagues indicate that the reformulated gel was three times less likely to cause cells in rectal tissue to release water and was equally effective against HIV as the vaginal formulation.

In the MTN-007 clinical trial presented at CROI, investigators noted lower rates of abdominal pain, urgent defecation, bloating, nausea and diarrhea among study volunteers who used the modified gel compared with those using the original formulation of the microbicide in an earlier trial.

When asked about the likelihood that they would use the gel in the future, 87 percent of the participants who used the rectal formulation of tenofovir gel indicated they would likely use the gel again, compared with 93 percent of the placebo gel group and 63 percent of those using rectal applications of a gel containing nonoxynol-9.

As a follow-up to MTN-007 and the laboratory data reported by Dezzutti and her colleagues, the federally funded MTN plans to conduct MTN-017, a Phase II clinical trial that will enroll nearly 200 men who have sex with men and transgender women in South Africa, Peru, Thailand and the United States.

Three regimens will be explored in the trial: Daily use of the rectal tenofovir gel, as-needed use of the gel (inserted before and after anal intercourse) and Truvada (tenofovir plus emtricitabine) taken orally every day.

Search: rectal, microbicide, anal, prevention, transmission, tenofovir, gel, viread, osmolarity, mtn, mtn-007, dezzutti

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.